Get the Stockscreener App
52.84
1.59%
0.855
Gsk Plc Adr stock is traded at $52.84, with a volume of 2.39M.
It is up +1.59% in the last 24 hours and down -10.66% over the past month.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
See More
Previous Close:
$51.99
Open:
$51.79
24h Volume:
2.39M
Relative Volume:
0.47
Market Cap:
$105.74B
Revenue:
$43.11B
Net Income/Loss:
$8.29B
P/E Ratio:
14.42
EPS:
3.6638
Net Cash Flow:
$5.71B
1W Performance:
-1.11%
1M Performance:
-10.66%
6M Performance:
+31.45%
1Y Performance:
+36.94%
1-Day Range:
$51.71
$52.91
1-Week Range:
$51.55
$52.91
52-Week Range:
$32.38
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Name
Gsk Plc Adr
Sector
Industry
Phone
-
Address
-
Compare GSK vs LLY, JNJ, ABBV, AZN, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
52.87 | 103.98B | 43.11B | 8.29B | 5.71B | 3.6638 |
LLY
Lilly Eli Co
|
902.49 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
234.77 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
204.94 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
184.99 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
115.72 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-06-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Nov-25-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-03-25 | Downgrade | Berenberg | Buy → Hold |
| Apr-15-25 | Initiated | Exane BNP Paribas | Neutral |
| Feb-12-25 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-15-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Nov-12-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-31-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-24 | Downgrade | UBS | Buy → Neutral |
| May-30-24 | Initiated | Goldman | Neutral |
| Mar-04-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-13-24 | Upgrade | Citigroup | Neutral → Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Jan-03-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Mar-17-23 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-27-23 | Resumed | Goldman | Buy |
| Jan-03-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Dec-05-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-11-22 | Downgrade | UBS | Neutral → Sell |
| Sep-15-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Sep-08-22 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-21-22 | Resumed | Citigroup | Neutral |
| Feb-11-22 | Downgrade | DZ Bank | Buy → Hold |
| Nov-05-21 | Upgrade | Barclays | Underweight → Equal Weight |
| Jun-24-21 | Upgrade | Deutsche Bank | Sell → Hold |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-04-21 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-20-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jan-15-21 | Initiated | Deutsche Bank | Hold |
| Nov-02-20 | Upgrade | Liberum | Hold → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Feb-12-20 | Downgrade | Shore Capital | Hold → Sell |
| Jan-16-20 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-19 | Initiated | SVB Leerink | Outperform |
| Nov-21-19 | Upgrade | UBS | Neutral → Buy |
| Oct-11-19 | Upgrade | Cantor Fitzgerald | Hold → Buy |
| Sep-03-19 | Resumed | Citigroup | Neutral |
| Sep-03-19 | Upgrade | Societe Generale | Sell → Buy |
| Aug-13-19 | Resumed | JP Morgan | Neutral |
| Jun-17-19 | Resumed | Morgan Stanley | Underweight |
| Mar-08-19 | Downgrade | Shore Capital | Buy → Hold |
| Feb-22-19 | Downgrade | UBS | Buy → Neutral |
| Jan-14-19 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
| Dec-11-18 | Resumed | Jefferies | Buy |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Aug-30-18 | Downgrade | Liberum | Buy → Hold |
| Apr-04-18 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Mar-22-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-09-18 | Upgrade | Kepler | Reduce → Hold |
View All
Gsk Plc Adr Stock (GSK) Latest News
GSK plc (ADR) stock surges on FDA approval for Lynavoy as pipeline momentum builds for 2026 - AD HOC NEWS
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK's Q4 earnings & sales beat estimates, stock up on '26 outlook - MSN
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Update - MarketBeat
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report - Benzinga
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults - Sahm
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Quantbot Technologies LP - MarketBeat
Price Over Earnings Overview: GSK - Sahm
GlaxoSmithKline Pharma: Can India’s GSK Arm Still Reward US Investors? - AD HOC NEWS
GSK PLC Sponsored ADR $GSK Shares Sold by Kahn Brothers Group Inc. - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Down 26.3% in February - MarketBeat
CapEx per share of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSKD - TradingView
Fisher Asset Management LLC Purchases 889,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play - Sahm
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Finviz
GSK (GSK) Announces 75.6% Vaccine Effectiveness for Arexvy in Real-World RSV Study - Finviz
Moderna Stock Jumps After FDA Reverses Course on Flu Shot - TradingView
GlaxoSmithKline Pharma: Quiet India Move, Big Signal for U.S. Portfolios? - AD HOC NEWS
GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17% - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Is GSK PLC Gaining or Losing Market Support? - Sahm
BI Asset Management Fondsmaeglerselskab A S Reduces Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Declares Dividend Increase$0.49 Per Share - MarketBeat
ANALYSIS-Novo Nordisk risks weight-loss price war as discount pressures deepen - Sahm
3 International Stocks to Buy for 2026 - Morningstar
GSK Set up for Steady Long-Term Growth as Portfolio and Pipeline Develop - Morningstar
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook - TradingView
10 best global blue-chip stocks to buy for the long term - Morningstar
GSK plc (ADR): Quiet Rally, Loud Expectations – Is the Stock Finally Escaping Its Legal Overhang? - AD HOC NEWS
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Gsk Plc Adr Stock (GSK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
0.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):